Timothy Lu

Corvium, Inc. engages in the development of fist synthetic biology-based bacterial monitoring platform. Its product include Control-Pro, an EMP automation software that converts data into action. The company was founded by Bob Langer, Timothy Lu, Michael Koeris, Brett Chevalier, Micah Rosenbloom, Tanguy Chau, and James J. Collins in March 2009 and is headquartered in Woburnc, MA.

Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA.

Engine Biosciences Pte Ltd. develops novel combinations of genes and drugs for therapeutic and industrial purposes. The company was founded by Timothy Lu and Jeffrey Lu and is headquartered in Singapore.

Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

Provectus Algae Pty Ltd. operates as a biotech company specialising in the optimisation of Algae to produce high-value compounds for a broad range of industries and applications. It offers natural and biosynthetic production services in antibiotics, vaccines, enzymes, cosmetics, hormones, terpenes, cannabinoids products.. The company was founded by Nusqe Spanton in 2018 and is headquartered in Noosaville, Australia.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Nest.Bio Ventures (Nest.Bio) is a venture capital firm founded in 2017. The firm is headquartered in Cambridge, Massachusetts.